Nov 1 (Reuters) - Pfizer Inc beat estimates for quarterly sales on Tuesday, as strong demand for older drugs helped offset lower demand for its COVID-19 products in international markets.
Pfizer reported third-quarter sales of $22.60 billion, beating the average analyst estimate of $21.04 billion, according to IBES data from Refinitiv.
Pfizer shares gained 2.3% in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments